



Last Name Sweet	First Name Christy	Middle Initial H.	Signature/Date: <i>Christy H. Sweet</i> 03MAR2018
Credentials: LPN, CCRP			Title: Clinical Research Manager
Study Site Address(es): WR-ClinSearch, LLC 6035 Shallowford Rd, Suite 109 Chattanooga, TN 37421			Contact Information Phone: 423-698-4584 Fax: 423-698-4577 Email: csweet@clinsearch-us.com
License No: State of Tennessee LPN0000070731 State of Georgia LPN071044			
Education and Training: Georgia Northwestern College, Rockspring, GA, Licensed Practical Nursing Program, 2004-2005 Floyd College, Rome, GA, Licensed Practical Nursing Program, 2003-2004			
Positions and Employment:			
<u>Date(s)</u>	<u>Title</u>	<u>Institution/Company</u>	
2016-Present	Clinical Research Manager	WR-ClinSearch, LLC, Chattanooga, TN	
2011-2016	Lead Clinical Research Nurse, Licensed Practical Nurse	ClinSearch, LLC, Chattanooga, TN	
2010-2011	Lead Clinical Research Nurse, Licensed Practical Nurse	Prism Research Group, Rome, GA	
2009-2010	Licensed Practical Nurse	Oak View Health and Rehabilitation, Summerville, GA	
2008-2009	Clinical Research Coordinator, Licensed Practical Nurse	ClinSearch, LLC, Chattanooga, TN	
2007-2008	Clinical Research Coordinator, Licensed Practical Nurse	Diagnostic Center, Chattanooga, TN	
2006-2007	Medical Records and Infection Control Nurse Manager	Forum Health Care, Rome, GA	
2005-2006	Licensed Practical Nurse	National Health Care, Rome, GA	
Professional Training/Licensure: CPR Certification OSHA—Blood Borne Pathogens Training IATA—Shipping Dangerous Goods Training Certified Clinical Research Professional, Society of Clinical Research Associates (SOCRA) Protecting Human Research Participants, National Institutes of Health (NIH) Human Subject Assurance Training, Office of Human Protections			
Clinical Study Phase Experience: I, II, III			
Clinical Research Experience: <u>Neurology</u>			
<ul style="list-style-type: none"> • A Phase IIb, Double Blinded, Randomized, Placebo Controlled, Dose-ranging Trial of XXXX for the Acute Treatment of Migraine • A Multi-Center, Double Blind, Randomized, Parallel-Group, Placebo-Controlled Study to Assess the Clinical Effect of XXXX in the Treatment of Symptomatic Neurogenic Orthostatic Hypotension in Patients with Parkinson's Disease • A Double-Blind, Randomized, Placebo-Controlled, Dose Escalating Study to Evaluate the Safety, Tolerability, and Immunogenicity of XXXX Formulated on Aluminum-Containing Adjuvant with or without XXXX in Patients with Alzheimer Disease • A Phase III, Multicenter, Randomized, Double-Blinded, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of XXXX in Patients with Primary Insomnia-Study B 			

- A Six Month Phase II/III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Safety, Tolerability, and Efficacy of XXXX for Prevention of Menstrually Related Migraine in Female Patients with Episodic Migraine
- A Randomized, Double-Blind, Placebo-Controlled, Subjective Study to Assess the Efficacy of XXXX in Patients with Primary Insomnia Characterized by Difficulty Maintaining Sleep
- A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of XXXX in Adult Migraineurs for a Single Migraine Followed by Open-Label Extensions to 26/52 Weeks
- A Phase IIb, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study of XXXX in the Treatment of Acute Migraine
- A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of XXXX in Patients with Migraine
- A Parallel Group, Double-Blind, Randomized, Placebo Controlled Phase 1b Trial to Evaluate the Safety, Pharmacokinetics, and Efficacy of A Single Dose of XXXX Administered Intravenously in Patients with Frequent Episodic Migraine
- A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of XXXX in Migraine Prevention
- A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Study of XXXX in Patients with Chronic Migraine
- A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Study of XXXX in Patients with Episodic Migraine

Gastroenterology

- A Double Blind, Randomized, Placebo-Controlled, Parallel Group Study to Assess the Safety and Efficacy of XXXX in Subjects with Opioid-Induced Constipation
- A Phase 3, Randomized, Double-Blinded, Placebo-controlled, Parallel-Treatment Group, Multicenter Efficacy and Safety Study of the Intra-Anal Application of XXXX in Subjects with Symptomatic Internal Hemorrhoids
- A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of XXXX in the Treatment of Patients with Irritable Bowel Syndrome with Diarrhea
- A Randomized, Double-Blinded, Placebo-Controlled Study to Assess the Safety and Efficacy of XXXX for the Treatment of Constipation-Predominant Irritable Bowel Syndrome
- A Phase 2, Double-Blinded, Placebo-Controlled Study to Evaluate the Safety and Efficacy of XXXX in Patients with Diabetic Gastroparesis
- A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Long-Term Safety and Tolerability of XXXX for the Treatment of Opioid-Induced Constipation in Adults Taking Opioid Therapy for Chronic Non-Cancer Pain
- A Pilot Study of XXXX Laxative in Adults Experiencing Non-Idiopathic Constipation

Musculoskeletal

- A Double Blinded, Randomized, Placebo-Controlled, Parallel Group, Multi-Site Study to Evaluate the Clinical Equivalence of XXXX with XXXX in Patients with Osteoarthritis of the Knee
- A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Pregabalin-Referenced, Parallel-Group, Adaptive Design Study of XXXX in Adult Female Outpatients with Fibromyalgia Syndrome
- A Phase 2, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study of XXXX in Patients with Fibromyalgia
- A Randomized, Double-Blind, Placebo and Active Controlled Study of XXXX in Subjects with Pain Associated with Fibromyalgia

Ophthalmology

- An Evaluation of the Efficacy and Safety of XXXX Ophthalmic Solution for the Treatment of Adenoviral Conjunctivitis
- A Randomized, Multicenter, Double-Masked, Parallel-Group Dose Ranging Clinical Safety and Efficacy Evaluation of XXXX Ophthalmic Suspension versus Vehicle for the Treatment of Inflammation Following Cataract Surgery

Metabolic

- A Multicenter, Randomized, Double-Blind Study of the Co-Administration of XXXX and ZZZZ in Patients with Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control
- A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate Cardiovascular Outcomes during Treatment with XXXX with Type 2 Diabetic Patients after an Acute Coronary Syndrome
- A 104-Week, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Assess the Safety and Efficacy of XXXX in Obese Patients
- A 52-Week, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Assess the Safety and Efficacy of XXXX in Overweight and Obese Patients with Type 2 Diabetes Mellitus Managed with Oral Hypoglycemic
- A 52-Week, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group to Assess the Safety and Efficacy of XXXX in Overweight and Obese Patients

- A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effect of Long Term Treatment with XXXX on the incidence of Major Adverse Cardiovascular Events of Major Adverse Cardiovascular Events and Conversion to type 2 Diabetes Mellitus in Obese and Overweight Subjects with Cardiovascular Disease or Multiple Cardiovascular Risk Factors

Rater Certifications:

CSSRS